Objective: To compare bariatric surgery versus intensive medical weight management (MWM) in patients with type 2 diabetes mellitus (T2DM) who do not meet current National Institutes of Health criteria for bariatric surgery and to assess whether the soluble form of receptor for advanced glycation end products (sRAGE) is a biomarker to identify patients most likely to benefit from surgery. Background: There are few studies comparing surgery to MWM for patients with T2DM and BMI less than 35. Methods: Fifty-seven patients with T2DM and BMI 30 to 35, who otherwise met the criteria for bariatric surgery were randomized to MWM versus surgery (bypass, sleeve or band, based on patient preference). The primary outcomes assessed at 6 months were change in homeostatic model of insulin resistance (HOMA-IR) and diabetes remission. Secondary outcomes included changes in HbA1c, weight, and sRAGE. Results: The surgery group had improved HOMA-IR (−4.6 vs +1.6; P = 0.0004) and higher diabetes remission (65% vs 0%, P < 0.0001) than the MWM group at 6 months. Compared to MWM, the surgery group had lower HbA1c (6.2 vs 7.8, P = 0.002), lower fasting glucose (99.5 vs 157; P = 0.0068), and fewer T2DM medication requirements (20% vs 88%; P < 0.0001) at 6 months. The surgery group lost more weight (7. vs 1.0 BMI decrease, P < 0.0001). Higher baseline sRAGE was associated with better weight loss outcomes (r = −0.641; P = 0.046). There were no mortalities. Conclusions: Surgery was very effective short-term in patients with T2DM and BMI 30 to 35. Baseline sRAGE may predict patients most likely to benefit from surgery. These findings need to be confirmed with larger studies.
U p to 78% of patients with type 2 diabetes mellitus (T2DM) may experience diabetes remission within 2 years after bariatric surgery. 1 Currently, only patients with T2DM and body mass index (BMI) greater than 35 are eligible for bariatric surgery. This is based on the 1991 National Institutes of Health (NIH) Guidelines and has been endorsed by the Centers for Medicare and Medicaid Services. 2 Patients with T2DM and BMI less than 35 are primarily offered intensive medical weight management (MWM), including pharmacotherapy and nonsurgical weight loss strategies. Millions of patients with T2DM have BMI less than 35, yet metabolic surgery is not an option for them. 3 There is emerging evidence supporting the use of bariatric surgery to treat diabetes in less obese (BMI < 35) patients. However, there are very few randomized trials. The Agency for Healthcare Research and Quality (AHRQ) recently identified this area as a research priority for comparative effectiveness research. 4 The NIH is unlikely to change the bariatric surgery guidelines for patients with T2DM without additional evidence to support such a change. 5 There is also an overall lack of treatment data in underrepresented minorities (especially Hispanics and non-Hispanic African-Americans) with T2DM, who are disproportionately affected by diabetes-related complications and mortality. Our municipal health care system serves a substantial number of these "hard-to-reach" minorities.
The receptor for advanced glycation end products (RAGE) binds multiple ligand families linked to hyperglycemia. Activation of RAGE plays a major role in the pathogenesis of diabetic vascular complications via activation of the nuclear factor κ β pathway. 6 Recent data indicate that mice devoid of RAGE who are fed high-fat diet are protected from diet-induced obesity and that the treatment of diabetic mice with a soluble form of RAGE (sRAGE) results in significantly reduced body weight gain versus vehicle-treated animals. 7 Interestingly, sRAGE already circulate in human plasma. sRAGE acts as a decoy to prevent an interaction between advanced glycation end products and RAGE and subsequent RAGE ligand-mediated effects on obesity and diabetes complications. 8 Therefore, levels of sRAGE may be innate biomarkers of vulnerability to obesity and diabetes and/or their severity. 9 The purpose of this study was twofold: (1) to conduct a pilot randomized trial to compare bariatric surgery to MWM in patients with T2DM and BMI 30 to 35 who otherwise met NIH criteria for surgery, and (2) to assess the role of sRAGE as a biomarker for predictor of success after surgery. Because of the fact that insurance companies typically cover bariatric surgery in patients with T2DM and BMI greater than 35, we partnered with our municipal health care system's primary insurer, who agreed to cover the costs of the surgery as part of this research project.
METHODS
We conducted a randomized controlled trial (RCT) among patients with T2DM and BMI 30 to 35 who were otherwise eligible for bariatric surgery by NIH criteria, specifically (1) overweight for at least 5 years, (2) failure to lose weight with nonsurgical means, (3) absence of medical or psychological contraindications, (4) patient understanding of the procedure and its risks, and (5) strong motivation to comply with the postsurgical regimen. Patients were excluded if they were deemed unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks), participation in other obesity-or diabetes-related clinical trials, or diagnosis of cognitive dysfunction or significant psychiatric comorbidity.
Our municipal health care system is the New York City Health and Hospitals Corporation (HHC). HHC is the public safety-net health care system of New York City. It is the largest municipal health care system in the United States, serving more than 1.4 million patients, including more than 475,000 uninsured city residents. HHC operates its own 400,000-member health plan-MetroPlus, which offers New York State-sponsored Medicaid-managed care to those who have been or are eligible for Medicaid and live in Brooklyn, Queens, Manhattan, and the Bronx. MetroPlus agreed to cover the costs of surgery and any associated complications of patients enrolled in this study.
Recruitment strategies included utilizing electronic medical records to identify patients with diabetes on the basis of International Classification of Diseases, Ninth Revision codes, notifying medical physicians of the study, sending out letters to all patients on various diabetes registries within our municipal health system, and partnering with MetroPlus to identify eligible patients.
Patients were screened for eligibility by study staff, provided informed consent by language-concordant research assistants, and then randomized to 1 of the 2 study arms ( Fig. 1 ). Patients were randomized by research assistants calling a central phone number to receive allocation; the allocation sequence was generated in advance and stratified to ensure balance of patients with BMI 30 to 35 in each of the arms. All data were collected using standard study templates, based on the CONSORT statement. 10 Institutional review board approval was obtained before enrolling the first patient.
Intensive MWM Protocol
The MWM protocol was based on successful models of lifestyle counseling previously published in the medical literature. [11] [12] [13] [14] These trials utilized intensive lifestyle interventions, including frequent group and individual sessions focusing on nutrition and physical activity counseling. For our short-term study, the weight loss goal was 5% of initial body weight at 6 months. MWM sessions were led by a bilingual weight loss clinician with an expertise in diabetes education. Sessions were held weekly for the first month and then biweekly. In these 30-minute sessions, the clinician offered culturally tailored, patient-specific counseling on diet, physical activity, self-monitoring, and goal setting. The visits included a review of home glucose data and adjustment of diabetes medications. In addition, participants were provided with pedometers to track their progress, with a goal of 150 minutes per week of lowimpact physical activity by 6 months.
Patients randomized to the MWM arm were given the option to cross over to the surgical arm after completing 6 months of MWM. The crossover group existed to ensure compliance with the MWM group, as a previous randomized study conducted at our institution (looking at a different research question involving MWM) suffered from high dropout/noncompliance in the MWM arm. 15 A minimum of 2% weight loss was required for all MWM participants to proceed with the surgery (to ensure maximum compliance with the MWM arm).
Bariatric Surgery Protocol
Patients randomized to surgery underwent bypass, band, or sleeve gastrectomy based on patient preference (drawing upon information learned in the monthly bariatric surgery information seminar and during the surgeon consultation). All patients underwent thorough evaluation by a surgeon, internist, nutritionist, and psychologist, and then completed a liquid protein diet for two weeks before surgery to decrease hepatomegaly.
Laparoscopic gastric bypass was performed with a 150-cm Roux limb and 100-cm biliopancreatic limb. Laparoscopic adjustable gastric banding was performed utilizing the pars flaccida technique and the Lap-Band AP Standard (California, Inamed). Sleeve gastrectomy was created over a 40Fr bougie, approximately 5 to 7 cm proximal to the pylorus, utilizing bioabsorbable buttressing material on the staple line. 16 Postoperative dietary guidelines were based on the ASMBS Allied Health Nutritional Guidelines for the surgical weight loss patient. 17 Patients were maintained on clear liquids for 48 hours postoperatively, then advanced to full liquid diet (including low-fat, low sugar, protein-rich shakes) for 2 weeks, followed by pureed diet for 2 weeks and then transitioned to regular diet. Patients were seen postoperatively at 2 weeks, 4 weeks and then monthly for the duration of the study. Band adjustments were done percutaneously in the clinic according to a commonly used algorithm based on hunger and weight loss. 18 ≥ 200 at 120 minutes after 75 g oral glucose load or (3) HbA1c ≥ 6.5%. 19 Diabetes remission was defined as no longer meeting the American Diabetes Association criteria for T2DM, without the use of diabetes medications.
The following study-related measures were collected at baseline and 6 months follow-up: insulin, glucose, glycated hemoglobin (HbA1c), weight, BMI, blood pressure, waist circumference, fasting lipids, blood pressure, and sRAGE. An oral glucose tolerance test (OGTT) was performed at 6 months on all patients, when not contraindicated (if fasting glucose was > 126 mg/dL, then the OGTT test was not performed). The patient was instructed to fast overnight and then was given a 75-g oral glucose load. Glucose levels were tested 120 minutes later. The homeostatic model of insulin resistance (HOMA-IR) was calculated as [(glucose mg/dL × insulin)/405]. Remission of diabetes and total and percentage excess weight loss (%EWL) were assessed at 6 months. Excess weight loss was calculated on the basis of the Robinson formula for ideal body weight. 20 Plasma sRAGE levels were assayed using enzyme-linked immunosorbent assay kits in accordance with the manufacturer's protocol (R&D Systems Quantikine Immunoassay Minneapolis, MN). The primary outcomes assessed at 6 months were (1) change in insulin resistance (HOMA-IR) and (2) diabetes remission.
Statistics
We calculated that 50 patients (25 in each arm) would constitute an adequately powered study to study both primary outcomes. The sample size for the primary outcome of change in HOMA-IR was assessed by calculating the size of detectable standard deviation units (SDU). The SDU corresponds to a beta coefficient in a regression model when we assume the standard normal deviate, ie N(0,1). Using an alpha error of 5%, we calculated that this study would have 80% power to detect an SDU of 0.81, corresponding to nearly one-fifth of the range of values. If we assume a similar distribution of HOMA-IR found in previous studies, 21 an SDU of 0.81 corresponds to a mean change in HOMA IR of 0.67. The sample size for the second primary outcome of diabetes remission was assessed by calculating the size of detectable difference in a binomial proportion. Using an alpha error of 5% and a diabetes remission rate of 13% in the MWM arm of a previous study, 21 we calculated that this study would have 80% power to detect a remission rate of 52% (ie, absolute change of 39%) in the bariatric surgery arm.
All study aims were tested on the basis of a 2-tailed significance level of 0.05. All analyses were intention-to-treat, that is, patients were analyzed according to the group they are assigned at randomization. SAS version 9.1 (SAS Institute, Cary, NC) was used for all data manipulations and statistical analysis. Demographic data was compared utilizing 2-sample t test or Fisher exact test, when applicable. Outcomes were compared using 2-sample t test, Fisher exact test, and analysis of variance test, when applicable. Scatter plots and Pearson correlation tests were used to evaluate the sRAGE biomarker as a predictor of success.
RESULTS
A total of 57 patients with T2DM and BMI 30 to 35 who otherwise met criteria for bariatric surgery were randomized to MWM (n = 28) or surgery (n = 29; bypass, sleeve, or band, based on patient preference). Demographics are shown in Table 1 . The patients randomized to surgery were slightly younger. The majority of patients were female Hispanic or non-Hispanic African-American, consistent with the patient population at our urban safety-net institution. Mean baseline HbA1c was 7.8 and 36% of patients were using insulin. Sleeve was the most popular procedure chosen by patients.
Ultimately, 44 patients (23% dropout rate) completed 6-month follow-up ( Fig. 2 ). Mean number of MWM visits for patients in 
Continuous data are presented as mean (SD) and were compared using a 2-sample t test; percentages were compared using the Fisher exact test.
LAGB indicates laparoscopic adjustable gastric banding; RYGB, laparoscopic Roux-en Y gastric bypass. the MWM arm was 11.5. Six-month follow-up in the surgery group was 95% (1 patient moved out of state). The surgery group had significantly improved HOMA-IR (−4.6 vs +1.6; P = 0.0004) and higher diabetes remission (65% vs 0%, P < 0.0001) than the MWM group at 6 months ( Table 2 ). The surgery group also had significantly lower HbA1c (6.2 vs 7.8, P = 0.002), lower fasting glucose (99.5 vs 157; P = 0.0068), lower glucose after oral glucose load (130.2 vs 306, P < 0.0001), and fewer T2DM medication requirements (20% vs 88%; P < 0.0001) at 6 months. The surgery group had significantly better weight loss outcomes (7.0 vs 1.0 BMI decrease, P < 0.0001) and change in waist circumference (−16.1 vs −1.8 cm, P < 0.0001) compared with the MWM group at 6 months (Table 3 ). There was no significant difference in lipid panels or blood pressure measurements, probably due to the fact that most patients had relatively normal lipid profiles and were normotensive at baseline.
When stratifying by surgery type, laparoscopic sleeve gastrectomy (LSG) had the highest rate of diabetes remission; however, this analysis was likely limited by the small sample size (Table 4 ). For instance, more patients who underwent bypass (3/6) were on insulin preoperatively compared to sleeve (1/11). When stratifying by baseline medication type, patients who were not using insulin at baseline had 80% remission after surgery, whereas those on insulin experienced 20% remission after surgery (P = 0.015).
Seven patients crossed over to surgery after completing the MWM arm. None of these experienced diabetes remission after the MWM intervention. However, after crossover to surgery, 3 patients (43%) experienced diabetes remission. These crossover patients had more significant BMI decrease (−6.4 vs −1.3; P = 0.0085) and increased %EWL (60.3% vs 10.8%, P = 0.004) after surgery. The change in HBA1c was not significant between the 2 groups in HBA1c (−0.6 vs −0.1; P = 0.722); however, the mean postsurgery follow-up was less than 6 months.
There was no association between pre-and posttreatment sRAGE with pre-and posttreatment characteristics, supporting the possibility of sRAGE as an independent biomarker ( Table 5 ). Higher baseline sRAGE was associated with better weight loss outcomes, P = 0.046 (Fig. 3 ). In the surgery group, mean sRAGE increased from 812 to 1044 pg/mL, but this was not significant (P = 0.319). In the MWM group, sRAGE decreased from 1162 to 995 pg/mL (P = 0.403).
There were no complications in the MWM arm. Hospitalizations unrelated to MWM were not tracked in this study. There were no mortalities or life-threatening complications in the surgery arm. There was 1 readmission with 30 days for dehydration (resolved with intravenous fluids and anti-emetics), and there was 1 late readmission (>30 days) for a trocar site abscess (resolved with percutaneous drainage and antibiotics).
DISCUSSION
There are very few RCTs focusing on the role of bariatric surgery in patients with T2DM and BMI 30 to 35. There are also very little data in Hispanics and non-Hispanic African-Americans with T2DM, who are disproportionately affected by diabetes and diabetes-related complications. The AHRQ has recognized this area as a critical research gap. There is an urgent need for large-scale RCTs comparing the effectiveness of bariatric surgery to MWM for patients with T2DM and BMI less than 35. The NIH is unlikely to change the guidelines without such data. There is also a need to determine which patients would benefit most from surgical intervention. Our pilot study found that surgery was very effective in the short-term in mainly Hispanic and non-Hispanic African-Americans with T2DM and BMI 30 to 35 (65% diabetes remission rate); we also found that higher baseline sRAGE correlated with improved weight-loss outcomes after surgery.
Our data are in accordance with previous studies in this area. We recently conducted a systematic review and meta-analysis of the existing data regarding bariatric surgery in patients with T2DM and BMI less than 35 (n = 1389) and calculated a 55% estimated diabetes remission rate at 12 months. 22 However, the bulk of the source data in this review were retrospective data. Most of the existing RCTs contain patients with BMI greater than 35. 21, [23] [24] [25] Two RCTs have been conducted in patients with T2DM and BMI less than 35; however, neither used MWM as the comparator arm. 26, 27 This is one of the first studies focusing on BMI 30 to 35 using MWM as the comparator arm. This pilot study may help design future larger-scale trials in this arena. Recruitment was a significant challenge at the outset, primarily due to the fact that most patients with BMI 30 to 35 did not consider themselves obese. Strategies to enhance patient recruitment included redesigning flyers to focus on diabetes remission (instead of weight loss), sending out flyers to patients on the diabetes registry in our system, and initiating group information seminars specifically tailored to patients with T2DM and BMI 30 to 35. A populationbased recruitment strategy may be the most pragmatic. 28 Also, sleeve was the most popular procedure chosen by patients randomized to surgery (mainly due to the lower risk profile compared to the bypass but greater efficacy than the band). Future studies should consider utilizing sleeve as the comparator. Future studies should also take into account the 23% dropout rate experienced in our study.
There are very little data about the clinical utility of sRAGE as a biomarker. sRAGE prevents activation of RAGE by advanced glycation end products. A recent study of 85 morbidly obese patients (who did not have T2DM) revealed that patients with morbid obesity have lower sRAGE compared with nonobese controls, and that sRAGE increases after bariatric surgery. 8 Our study also found an increase in sRAGE after bariatric surgery; however, it was not statistically significant, probably due to the limited sample size. Baseline sRAGE may have the potential to be a biomarker of diabetes. 9 We did find that baseline sRAGE correlated with weight loss after bariatric surgery. This implies that baseline sRAGE levels may be useful to predict T2DM patients most likely to benefit from surgical intervention for weight loss. This finding needs to be corroborated with larger-scale studies with longer follow-up.
Limitations of this study include the small sample size and the short-term duration (6 months). The original intent of this study was to conduct a pilot RCT to establish the groundwork for a larger longer-term study. We plan to follow this patient cohort and reanalyze the HOMA-IR and diabetes remission rate at 1 and 2 years. Because of the small sample size, we were unable to reliably compare band, bypass, and sleeve on diabetes outcomes. Furthermore, once patients were randomized to surgery, the actual procedure of selection was determined by the patient (ie, patients were not randomized to a particular procedure). Therefore, our finding that the sleeve had the highest diabetes remission rate is likely due to small sample size and/or selection bias (more severe T2DM patients had bypass compared to sleeve).
Another potential criticism of this study is that the comparator arm was MWM, not "intensive diabetes management," specifically that the comparator arm did not titrate diabetes medications to achieve better glycemic control. However, the aim of this study was to evaluate indices of insulin resistance (HOMA-IR) and T2DM remission, not diabetes control. Aggressively titrating diabetes medications is unlikely to improve HOMA-IR or induce T2DM remission. Weight loss and lifestyle modifications are the primary methods of improving insulin resistance and inducing T2DM remission. Our MWM arm could have perhaps integrated more extensive lifestyle changes (eg, using validated tools, requiring group visits, offering cooking classes, guided exercise regimens, and behavior psychology visits, etc); however, the frequency of our MWM was more than most MWM arms in previous comparative studies looking at similar outcomes. 21, 23 A recent study comparing MWM to surgery in morbidly obese patients (mean BMI 36) with more severe T2DM (mean HbA1c 9.2) revealed a 42% diabetes remission rate after sleeve gastrectomy. 23 Interestingly, they found comparable hospitalization/readmission rates (9%) in the MWM group (including hospitalizations unrelated to MWM) and the sleeve group, likely due to the consequences of severe, poorly controlled diabetes. A different study comparing MWM to gastric banding in morbidly obese patients (mean BMI 37) with recently diagnosed T2DM (mean HbA1c 7.7) found a 73% remission rate. 21 Our study, performed in a less obese population (mean BMI 32) with T2DM (mean HBA1c 7.8), revealed a 65% remission rate. Clinicians should consider earlier referral of obese patients with T2DM for bariatric surgery, as this may lead to a more significant impact on T2DM.
CONCLUSIONS
Bariatric surgery was very effective in the short-term in patients with T2DM and BMI 30 to 35. Surgery improved insulin resistance significantly compared to MWM and the short-term remission rate was 65%. Baseline sRAGE may predict patients most likely to benefit from surgery. These findings need to be confirmed with larger studies. 
DISCUSSANTS J. Morton (Stanford, CA):
No field of surgery has seen as many changes in perception, safety, or effectiveness in the last decade as bariatric surgery. We were once consigned to a cosmetic procedure, but now we're seen as rightly being a first responder to the obesity crisis. In that role, we can see that bariatric surgery can serve as a mirror for the physiology of obesity, revealing the powerful role that the surgery can play in metabolic disease.
In this study, we see the comparative effectiveness of bariatric surgery to medical management for diabetes in the lower BMI setting. Although the data for this intervention are few, evidence is emerging that bariatric surgery is safe and effective in this population. With the advent of the accountable care organizations, we are going to see more emphasis on accounting for hemoglobin A1c control.
Payers are recognizing the favorable impact of bariatric surgery for the diabetic patient. In fact, in the past year, Blue Cross Technology Evaluation Center has endorsed laparoscopic gastric bypass surgery as an intervention for BMI less than 35. Therefore, your paper is timely and important, and I want to commend your study on 3 different points.
First of all, it's a randomized trial, which is difficult to achieve in surgery. Second, you were able to do this RCT in a safety net hospital. Third, you were able to do it in a very interesting population; namely, diabetics with BMI 30 to 35.
I do have a few questions for you. The first question is, you currently have follow-up at 6 months. Do you plan on further follow-up?
The second question is, if we look at the recent 3-year data from the Stampede trial, which is also an RCT, looking at the demonstrated surgical superiority for diabetes treatment, it's interesting to note that the medical arm and the sleeve gastrectomy arm had equivalent adverse event rates. I would like you to comment a little about the comparative safety profile of each intervention.
The remission of diabetes is pretty impressive. The one thing I noticed was that in the paper there wasn't a corresponding improvement in the cardiac risk profile; namely, the lipids. If you could, please comment on why we didn't see an improvement in the cardiac risk factors.
Finally, given your study, do you think this calls for earlier referral for these patients?
Response From M. Parikh:
As far as the first question is concerned, yes, we are continuing to follow them in our program. As a matter of fact, part of the MWM arm included a crossover. Seven of the patients in the MWM arm crossed over to surgery and 3 of these patients experienced diabetes remission.
The second question about the Stampede trial concerned the reported BMIs, which ranged from 27 to 42, with a mean BMI of 36, which was a little bit higher than ours. We did not look at the medical hospitalization of the patients in the MWM group. I would suspect ours would have been lower, though, because the patients in that study were generally sicker as reflected in a higher A1c. I think the baseline A1c was 9.2, compared to 7.8 in ours.
In terms of the lipid profile, we did not see a difference, probably because most of the patients were not hyperlipidemic, and the vast majority was not on statins at baseline. I agree it is probably worthwhile for earlier referral, because it has been shown in the bariatric literature in the patients with BMI 35 and higher that you have a greater benefit with patients who have less duration of diabetes or less severe diabetes, and the surgical risk is probably lower as well.
DISCUSSANTS

B. Wolfe (Portland, OR):
There have been several randomized trials comparing medical to surgical intervention for type 2 diabetes. It is quite remarkable that the findings have been essentially identical in all of these trials demonstrating the superiority of surgical intervention in inducing remission of type 2 diabetes.
My question relates to the weight loss. The criteria for entry was less severe obesity than is the standard in bariatric surgery at present, yet important weight loss still occurred in your trial. Are you able to make any observations about the role of specific operative procedures or the weight loss in accomplishing remission of diabetes?
Response From M. Parikh:
Yes. I think the diabetes remission was primarily weight loss driven. The percent excess weight loss was 7% in the MWM group and 60% in the surgery group. The surgery group lost 7 BMI points, and the MWM group lost 1 BMI point.
DISCUSSANTS D. Flum (Seattle, WA):
Having just been through our own RCT randomization process and seeing a dropout rate that is considerable, maybe you can comment a little bit about how the patients were prepared and selected. We put our patients, about a thousand patients, through a shared decisionmaking activity to find those in equipoise and willing to undergo a randomization so that we could avoid this dropout rate. It was still problematic. I would love to be see how you recruited, educated, and got a group of patients that you think were in equipoise.
The second comment, I would just love to hear a discussion about this issue of an endpoint. There is a debate going on about whether or not it's reasonable to expect patients who are treated medically for diabetes to essentially come off their diabetes medications or whether or not the goal should be management on medication rather than off all medications. So, it's a bit of a debate, and I think the audience could benefit from your opinion on that debate.
Response From M. Parikh:
It is difficult to establish equipoise. I think that is part of the problem with recruitment for a randomized trial comparing surgery to medical treatment in general. In our manuscript, we reference the paper that you all put out about recruiting patients for this, because I agree that you have to end up using a population-based strategy to recruit. We went from trying to approach patients directly to just sending letters out to the registry and seeing who contacted us.
The biggest challenge is if you randomize patients that want surgery to a MWM arm, they will not comply with MWM. That is a challenge that was very difficult. That was one of the reasons why we had the crossover arm that allowed them to cross over as long as they participated in the MWM arm.
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